share_log

Daré Bioscience Announces Publication In Contraception Of Efficacy And Safety Findings From A Pre-Pivotal Postcoital Test Study Of Ovaprene: An Investigational Hormone-Free Monthly Intravaginal Contraceptive

Benzinga ·  Apr 11 20:15

Published data shows that Ovaprene was safe and effective in a postcoital test study of 33 women

Pivotal Phase 3 contraceptive efficacy clinical study of Ovaprene currently enrolling

Ovaprene has the potential to be the first FDA-approved hormone-free monthly intravaginal contraceptive for women

SAN DIEGO, April 11, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women's health innovation, today announced the publication of data from the postcoital test clinical study of Ovaprene in two original research articles in the journalContraception.

Publication Details:

Mauck, et al. "Successful postcoital testing of Ovaprene: An investigational non- hormonal monthly vaginal contraceptive."...

Login or create a forever free account to read this news
Sign up/Log in
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment